Psychotomimesis Mediated by κ Opiate Receptors
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The κ opioid agonists are analgesics that seem to be free of undesired morphine-like effects. Their dysphoric actions observed with the κ agonist cyclazocine are thought to be mediated by an action at σ-phencyclidine receptors. The benzomorphan κ agonist MR 2033 is inactive at σ-phencyclidine receptors. In male subjects, the opiate-active (-)-isomer, but not the (+)-isomer, elicited dose-dependent dysphoric and psychotomimetic effects that were antagonized by naloxone. Thus, κ opiate receptors seem to mediate psychotomimetic effects. In view of the euphorigenic properties of μ agonists, our results imply the existence of opposed opioid systems affecting emotional and perceptual experiences.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“agonism of κ-opioid receptors were shown to produce depression-like symptoms in humans (Pfeiffer et al., 1986).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Pfeiffer et al., 1986
In the citing paper
“Nonetheless, the three receptor types have different behavioral domains, with MOR and DOR mediating generally positive motivation and affect, while KOR mediates generally negative motivation and aversion (Pfeiffer et al 1986; Shippenberg et al 1987; Pecina and Berridge 2000; McLaughlin et al 2003; for reviews see Van Ree et al 2000; Le Merrer et al 2009).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Pfeiffer et al 1986
In the citing paper
“Kappa receptor agonists induce anxiogenic and dysphoric effects in humans (141-143) and depressive-like behavior in animals (i.e., increased immobility in the forced swim test) (144, 145).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [141]
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man
Domino, E. F., Chodoff, P., & Corssen, G. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563279 · Cited by 748
Martin, W. R. (1983) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06637-2 · Cited by 648
Thrills in response to music and other stimuli
Goldstein, A. (1980) · Physiological Psychology · doi:10.3758/bf03326460 · Cited by 522
Mucha, R. F., & Herz, A. (1985) · Psychopharmacology · doi:10.1007/bf00432213 · Cited by 510
Self-citationThe binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties
Magnan, J., Paterson, S. J., Tavani, A., & Kosterlitz, H. W. (1982) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00495865 · Cited by 509
A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS
TYERS, M. B. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb07041.x · Cited by 341
Opiate receptor binding sites in human brain
Pfeiffer, A., Pasi, A., Mehraein, P., & Herz, A. (1982) · Brain Research · doi:10.1016/0006-8993(82)91150-7 · Cited by 298
Self-citationPhencyclidine (angel dust)/sigma "opiate" receptor: visualization by tritium-sensitive film.
Quirion, R., Hammer, R. P., Herkenham, M., & Pert, C. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5881 · Cited by 254
Research works printed but not linked: 6
- Jasinski, D. R., Drug Addiction 1: 216 (1977).
- MARTIN, W.R., PHARMACOL REV 35: 283 (1984).
- MARTIN, W.R., SUBSTANCE AND ALCOHOL ACTIONS/MISUSE 1: 269 (1980).
- Shearman, G. T., Drug Discrimination: Application in CNS Pharmacology: 37 (1982).
- VAUPEL, D.B., FAILURE OF NALTREXONE (NTX) TO ANTAGONIZE PHENCYCLIDINE (PCP) AND THE OPIOID SKF-10047 (SKF) IN THE DOG, FEDERATION PROCEEDINGS 41: 1333 (1982).
- Zerssen, D. V., Assessment of Depression: 270 (1985).
Cited by
Items 401–500 of 956
Huang, P., Tunis, J., Parry, C., Tallarida, R. J., & Liu‐Chen, L. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.061 · Cited by 32
Nguyen, E. K., Lim, G., & Ross, S. E. (2021) · Anesthesiology · doi:10.1097/aln.0000000000003844 · Cited by 32
Chen, Z., Tang, Y., Tao, H., Li, C., Zhang, X., & Liu, Y. H. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.030 · Cited by 32
Emerging Treatment Targets for Migraine and Other Headaches
Bertels, Z., & Pradhan, A. A. A. (2019) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13585 · Cited by 32
The atypical antidepressant mianserin exhibits agonist activity at κ‐opioid receptors
Olianas, M. C., Dedoni, S., & Onali, P. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02078.x · Cited by 32
Braida, D., Donzelli, A., Martucci, R., Capurro, V., & Sala, M. (2011) · International Journal of Toxicology · doi:10.1177/1091581811418538 · Cited by 32
Lendeckel, U., Kähne, T., ten Have, S., Bukowska, A., Wolke, C., Bogerts, B., Keilhoff, G., & Bernstein, H. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.01.011 · Cited by 32
Mello, N. K., Mendelson, J. H., Sholar, M. B., Jaszyna-Gasior, M., Goletiani, N. V., & Siegel, A. J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300631 · Cited by 32
Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models
Havel, V., Kruegel, A. C., Bechand, B., McIntosh, S., Stallings, L. S., Hodges, A., Wulf, M. G., Nelson, M., Hunkele, A., Ansonoff, M. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51856-y · Cited by 31
Arrestin-Mediated Activation of p38 MAPK: Molecular Mechanisms and Behavioral Consequences
Chavkin, C., Schattauer, S. S., & Levin, J. R. (2013) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-41199-1_14 · Cited by 31
Li, S., Cai, Z., Zheng, M., Holden, D., Naganawa, M., Lin, S.-F., Ropchan, J. R., Labaree, D. C., Kapinos, M., Lara‐Jaime, T., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.195586 · Cited by 31
Ragen, B., Maninger, N., Mendoza, S. P., & Bales, K. L. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.11.053 · Cited by 31
Sherwood, A. M., Crowley, R. S., Paton, K. F., Biggerstaff, A., Neuenswander, B., Day, V. W., Kivell, B. M., & Prisinzano, T. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00148 · Cited by 31
Lagard, C., Chevillard, L., Guillemyn, K., Risède, P., Laplanche, J., Spetea, M., Ballet, S., & Mégarbane, B. (2016) · Pain · doi:10.1097/j.pain.0000000000000790 · Cited by 31
Incorporating the assessment of abuse liability into the drug discovery and development process
Mansbach, R. S., Feltner, D. E., Gold, L. H., & Schnoll, S. H. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00100-5 · Cited by 31
Jolivalt, C. G., Jiang, Y., Freshwater, J. D., Bartoszyk, G. D., & Calcutt, N. A. (2006) · Diabetologia · doi:10.1007/s00125-006-0397-y · Cited by 31
Synthesis and in vitro pharmacological studies of new C(4)-modified salvinorin A analogues
Lee, D. Y. W., He, M., Liu‐Chen, L., Wang, Y., Li, J.-G., Xu, W., Ma, Z., Carlezon, W. A., & Cohen, B. M. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.051 · Cited by 31
Opiates and deer mouse behaviour: differences between island and mainland populations
Innes, D. G. L., & Kavaliers, M. (1987) · Canadian Journal of Zoology · doi:10.1139/z87-378 · Cited by 31
Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist
Zhou, Y., Freeman, K. B., Setola, V., Cao, D., Kaski, S. W., Kreek, M. J., & Liu‐Chen, L. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_443 · Cited by 30
Shram, M. J., Spencer, R. H., Qian, J., Munera, C. L., Lewis, M. E., Henningfield, J. E., Webster, L. R., & Menzaghi, F. (2021) · Clinical and Translational Science · doi:10.1111/cts.13173 · Cited by 30
Wang, Y., Hang, A., Lu, Y., Long, Y., Zan, G., Li, X., Wang, Q., Zhao, Z., He, L., Chi, Z., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.022 · Cited by 30
Shen, Q., Deng, Y., Ciccocioppo, R., & Cannella, N. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00234 · Cited by 30
Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence
Nomura, A., Ujike, H., Tanaka, Y., Otani, K., Morita, Y., Kishimoto, M., Morio, A., Harano, M., Inada, T., Yamada, M., et al. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.02.038 · Cited by 30
Bjørnebekk, A., Mathé, A. A., Gruber, S. H. M., & Brené, S. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008912 · Cited by 30
Jones, H. E., Bigelow, G. E., & Preston, K. L. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38279-5 · Cited by 30
3 Chemical Structures and Biological Activities of Non-Peptide Selective Kappa Opioid Ligands
Rees, D. C. (1992) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70006-7 · Cited by 30
Cahill, C. M., Tejeda, H. A., Spetea, M., Chen, C., & Liu‐Chen, L. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_433 · Cited by 29
Prisinzano, T. E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400388u · Cited by 29
Morani, A. S., Ewald, A. W. M., Prevatt‐Smith, K. M., Prisinzano, T. E., & Kivell, B. M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.10.050 · Cited by 29
Chen, C., Chiu, Y.-T., Wu, W., Huang, P., Mann, A., Schulz, S., & Liu‐Chen, L. (2015) · Biochemical Journal · doi:10.1042/bj20141471 · Cited by 29
Jomary, C., Gairin, J. E., Cros, J., & Meunier, J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.2.627 · Cited by 29
Repeated naloxone administration in schizophrenia: A phase II world health organization study
Pickar, D., Bunney, W. E., Douillet, P., Sethi, B. B., Sharma, M., Vartanian, M. E., Rr, L., Naber, D., Leibl, K., Yamashita, I., et al. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90197-2 · Cited by 29
Ni, Q., Xu, H., Partilla, J. S., de Costa, B. R., Rice, K. C., & Rothman, R. B. (1993) · Peptides · doi:10.1016/0196-9781(93)90188-m · Cited by 29
Psychiatric neural networks and neuropharmacology: Selected advances and novel implications
Ghanemi, A. (2013) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.01.008 · Cited by 28
Rogala, B., Li, Y., Li, S., Chen, X., & Kirouac, G. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049669 · Cited by 28
Bradford, C. S., Walthers, E. A., Searcy, B. T., & Moore, F. L. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01711 · Cited by 28
Discriminative Stimulus Effects of the Nonpeptidic δ-Opioid Agonist SNC80 in Rhesus Monkeys
Brandt, M. R., Negus, S. S., Mello, N. K., Furness, M. S., Zhang, X., & Rice, K. C. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35018-9 · Cited by 28
Measurement of CSF dynorphin a 1–8 immunoreactivity in anorexia nervosa and normal-weight bulimia
Lesem, M. D., Berrettini, W. H., Kaye, W. H., & Jimerson, D. C. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)91286-z · Cited by 28
Induction of Fos-like immunoreactivity by opioids in guinea-pig brain
Bot, G., & Chahl, L. A. (1996) · Brain Research · doi:10.1016/0006-8993(96)00457-x · Cited by 28
Anand, J. P., Purington, L. C., Pogozheva, I. D., Traynor, J. R., & Mosberg, H. I. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12014 · Cited by 27
Huskinson, S. L., Platt, D. M., Zamarripa, C. A., Dunaway, K., Brasfield, M., Prisinzano, T. E., Blough, B. E., & Freeman, K. B. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173394 · Cited by 27
Tejeda, H. A., Chefer, V. I., Zapata, A. G., & Shippenberg, T. S. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1799-6 · Cited by 27
Inhibition of morphine tolerance by processed Aconiti tuber is mediated by kappa-opioid receptors
Shu, H., Arita, H., Hayashida, M., Chiba, S., Sekiyama, H., & Hanaoka, K. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.01.004 · Cited by 27
Opioid modulation of cognitive impairment in depression
Jacobson, M. L., Wulf, H. A., Browne, C. A., & Lucki, I. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.07.007 · Cited by 27
Ko, M., Willmont, K. J., Lee, H., Flory, G. S., & Woods, J. H. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02938-x · Cited by 27
Phencyclidine: A Drug of Abuse and a Tool for Neuroscience Research
Balster, R. L., & Willetts, J. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-60963-3_6 · Cited by 27
Emotions, Brain, Immunity, and Health: A Review
Melnechuk, T. (1988) · Springer eBooks · doi:10.1007/978-1-4757-1987-1_8 · Cited by 27
Opioid Receptors and their Ligands: Recent Developments
CASY, A. F. (1989) · Advances in Drug Research · doi:10.1016/b978-0-12-013318-5.50008-4 · Cited by 27
Motivational Effects of Opioids
Shippenberg, T. S. (1993) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-77540-6_26 · Cited by 27
Signaling underlying kappa opioid receptor-mediated behaviors in rodents
Liu‐Chen, L., & Huang, P. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.964724 · Cited by 26
Lockie, S. H., Czyzyk, T. A., Chaudhary, N., Pérez–Tilve, D., Woods, S. C., Oldfield, B. J., Statnick, M. A., & Tschöp, M. H. (2011) · Endocrinology · doi:10.1210/en.2011-1220 · Cited by 26
Sacharczuk, M., Juszczak, G. R., Swiergiel, A. H., Jaszczak, K., Lipkowski, A. W., & Sadowski, B. (2009) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2009-1757 · Cited by 26
Bailey, S., & Husbands, S. M. (2018) · Neuronal Signaling · doi:10.1042/ns20170145 · Cited by 26
Pharmacotherapy of personality disorders
Triebwasser, J., & Siever, L. J. (2007) · Journal of Mental Health · doi:10.1080/09638230601182078 · Cited by 26
Attenuation of morphine tolerance and withdrawal syndrome by coadministration of nalbuphine
Jang, S., Kim, H., Kim, D., Jeong, M. W., Ma, T., Kim, S., Ho, I. K., & Oh, S. (2006) · Archives of Pharmacal Research · doi:10.1007/bf02968252 · Cited by 26
Butelman, E. R., Ball, J., & Kreek, M.-J. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1195-y · Cited by 26
Central and peripheral actions of the novel κ‐opioid receptor agonist, EMD 60400
Barber, A., Bartoszyk, G. D., Greiner, H. E., Mauler, F., Murray, R. D., Seyfried, C. A., Simon, M., Gottschlich, R., Harting, J., & Lues, I. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb14815.x · Cited by 26
Sex differences in the modulation of mouse nest building behavior by kappa opioid receptor signaling
Jacobson, M. L., Wulf, H. A., Tsuda, M. C., Browne, C. A., & Lucki, I. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108254 · Cited by 25
Secondulfo, C., Mazzeo, F., Pastorino, G. M. G., Vicidomini, A., Meccariello, R., & Operto, F. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179407 · Cited by 25
Walker, B. M. (2012) · Alcohol · doi:10.1016/j.alcohol.2012.01.001 · Cited by 25
Zádor, F., Lénárt, N., Csibrány, B., Sántha, M., Molnar, M. F., Tuka, B., Samavati, R., Klivènyi, P., Vécsei, L., Marton, A., et al. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.008 · Cited by 25
Pani, P. P., Maremmani, A. G. I., Trogu, E., Vigna‐Taglianti, F., Mathis, F., Diecidue, R., Kirchmayer, U., Amato, L., Davoli, M., Ghibaudi, J., et al. (2015) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0000000000000072 · Cited by 25
The price of seizure control: Dynorphins in interictal and postictal psychosis
Bortolato, M., & Solbrig, M. V. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2006.11.004 · Cited by 25
The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders
Bourin, M., & Prica, C. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.03.001 · Cited by 25
Rothman, R. B., Xu, H., Char, G. U., Kim, A., de Costa, B. R., Rice, K. C., & Zimmerman, D. M. (1993) · Peptides · doi:10.1016/0196-9781(93)90005-2 · Cited by 25
Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging
Placzek, M. S., Schroeder, F. A., Che, T., Wey, H., Neelamegam, R., Wang, C., Roth, B. L., & Hooker, J. M. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00293 · Cited by 24
Qian, H., Wei, Y., Liu, X., Ye, R., Kong, L., Li, Z., Jiang, S., Yu, L., Chai, J., Xie, Q., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01082 · Cited by 24
Adžić, M., Lukić, I., Mitić, M., Glavonic, E., Dragicevic-Curic, N., & Ivković, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121803 · Cited by 24
Biological framework for traumatic dissociation related to early life trauma
Christian, S., Lanius, R. A., Pain, C. C., & Vermetten, E. H. G. J. M. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777042.021 · Cited by 24
Almatroudi, A., Ostovar, M., Bailey, C. P., Husbands, S. M., & Bailey, S. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14060 · Cited by 24
Altarifi, A., Yuan, Y., Zhang, Y., Selley, D. E., & Negus, S. S. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3719-7 · Cited by 24
Apparent efficacy of κ-opioid receptor ligands on serum prolactin levels in rhesus monkeys
Butelman, E. R., Harris, T. J., & Kreek, M.-J. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00640-8 · Cited by 24
Shu, H., Arita, H., Hayashida, M., Sekiyama, H., & Hanaoka, K. (2005) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2005.08.017 · Cited by 24
Analgesic Drugs Combinations in the Treatment of Different Types of Pain
Ortiz, M. I., Molina, M. A. R., Arai, Y.-C. P., & Romanò, C. L. (2012) · Pain Research and Treatment · doi:10.1155/2012/612519 · Cited by 24
Laman-Maharg, A., Copeland, T., Sanchez, E. O., Campi, K. L., & Trainor, B. C. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.06.015 · Cited by 23
Cueva, J. P., Cai, T., Mascarella, S. W., Thomas, J. B., Navarro, H. A., & Carroll, F. I. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900756t · Cited by 23
Atigari, D. V., Uprety, R., Pasternak, G. W., Majumdar, S., & Kivell, B. M. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.010 · Cited by 23
In Silico Identification of Tripeptides as Lead Compounds for the Design of KOR Ligands
Stefanucci, A., Iobbi, V., Valle, A. D., Scioli, G. A., Pieretti, S., Minosi, P., Mirzaie, S., Novellino, E., & Mollica, A. (2021) · Molecules · doi:10.3390/molecules26164767 · Cited by 23
Valenza, M., Windisch, K. A., Butelman, E. R., Reed, B., & Kreek, M. J. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05444-4 · Cited by 23
Increased rewarding properties of morphine in perinatally protein-malnourished rats
Valdomero, A., Velazquez, E. E., de Olmos, S., de Olmos, J. S., Orsingher, O. A., & Cuadra, G. R. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.09.006 · Cited by 23
Kobayashi, T., Ikeda, K., Ichikawa, T., Togashi, S., & Kumanishi, T. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15679.x · Cited by 23
Li, Z. (2012) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.s7-007 · Cited by 22
Toward the Identification of a Specific Psychopathology of Substance Use Disorders
Maremmani, A. G. I., Pani, P. P., Rovai, L., Bacciardi, S., & Maremmani, I. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00068 · Cited by 22
Advances in the Treatment of Chronic Pain by Targeting GPCRs
Che, T. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00644 · Cited by 22
Genetic and early environmental contributions to alcohol's aversive and physiological effects
Roma, P. G., Rinker, J. A., Serafine, K. M., CHEN, S., Barr, C., CHENG, K., Rice, K. C., & Riley, A. L. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.06.022 · Cited by 22
Psychotomimetic Effects of Kappa Opioid Receptor Agonists
White, K. L., & Roth, B. L. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.08.014 · Cited by 22
Schizophrenia: pathophysiological mechanisms — a synthesis
Terenius, L. Y. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00057-0 · Cited by 22
Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits
Davis, M. P. (2025) · Drugs · doi:10.1007/s40265-024-02128-y · Cited by 21
Opioids differentially modulate two synapses important for pain processing in the amygdala
Kissiwaa, S. A., Patel, S., Winters, B. L., & Bagley, E. E. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14877 · Cited by 21
Ferracane, M. J., Brice‐Tutt, A. C., Coleman, J. S., Simpson, G. G., Wilson, L., Eans, S. O., Stacy, H. M., Murray, T. F., McLaughlin, J. P., & Aldrich, J. V. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00086 · Cited by 21
Atigari, D. V., Paton, K. F., Uprety, R., Váradi, A., Alder, A. F., Scouller, B., Miller, J. H., Majumdar, S., & Kivell, B. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108445 · Cited by 21
Translational value of non-human primates in opioid research
Ding, H., & Ko, M. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113602 · Cited by 21
Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive Disorder
Browne, C. A., Wulf, H. A., & Lucki, I. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2020_432 · Cited by 21
Oña, G., Sampedro, F., Romero, S., Valle, M., Camacho, V., Migliorelli, C., Mañanas, M. Á., Antonijoan, R. M., Puntes, M., Coimbra, J., et al. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab063 · Cited by 21
Huang, Q., Sun, M., Chen, Y., Li, X., & Wang, Y. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.12.027 · Cited by 21
Murkin, J. M. (1991) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1016/1053-0770(91)90288-5 · Cited by 21
Creighton, C. J., Ramabadran, K., Ciccone, P. E., Liu, J., Orsini, M. J., & Reitz, A. B. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.05.018 · Cited by 21
Campi, C. C., & Clarke, G. D. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)00384-u · Cited by 21
Human Pharmacology of the Opioid Neuropeptide Dynorphin A(1–13)
Greenwald, M. K., Stitzer, M. L., & Haberny, K. A. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36704-7 · Cited by 21
Friderichs, E., Christoph, T., & Buschmann, H. (2007) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a02_269.pub2 · Cited by 21
Metadata
- Authors
- Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M.
- Affiliations
- LMU Klinikum (DE)
- Boehringer Ingelheim (Germany) (DE)
- Max Planck Society (DE)
- Max Planck Institute of Psychiatry (DE)
- ORCID
- Pfeiffer, Andreas
- Venue
- Science
- Published
- 1986-08-15
- Volume
- 233
- Issue
- 4765
- Pages
- 774-776
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2032643119
- Cited by
- 857
- References
- 30
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 23 · 2023: 17 · 2022: 18 · 2021: 38 · 2020: 42 · 2019: 21 · 2018: 27 · 2017: 24 · 2016: 37 · 2015: 38 · 2014: 30 · 2013: 35 · 2012: 41
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psychotomimetic effects, kappa opioid receptor, kappa opioid receptor agonists, cyclazocine, naloxone antagonism, stereoisomers, mu-opioid receptor agonists, euphoria, analgesia
- MeSH terms
- Adult, Anxiety, Benzomorphans, Humans, Male, Middle Aged, Morphinans, Naloxone, Personality Tests, Phencyclidine, Receptors, Opioid, Receptors, Opioid, kappa
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.